Stock Events

Stock Events

Northwest Biotherapeutics 

€0.160000
91
+€0.03+23.08% 10:16 Today

Statistics

Day High
0.19
Day Low
0.13
52W High
0.38
52W Low
0.1
Volume
7,500
Avg. Volume
-
Mkt Cap
267.09M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Financials

-4,474.79%Profit Margin
Unprofitable
2020
2021
2022
2023
2024
2025
1.2MRevenue
-53.74MNet Income

People Also Follow

This list is based on the watchlists of people on Stock Events who follow NBYB.STU. It's not an investment recommendation.
Amazon
13
AMZN
Realty Income
11
O
Apple
10
AAPL
Microsoft
10
MSFT

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Marker Therapeutics
MRKR
Mkt Cap16.34M
Marker Therapeutics, Inc. is involved in developing T cell-based immunotherapies for cancers, competing in the cellular therapy space.
Novartis
NVS
Mkt Cap303.67B
Novartis AG has a broad portfolio including cancer immunotherapies, competing on a larger scale with NWBO's cancer treatments.
Bristol-Myers Squibb
BMY
Mkt Cap127.71B
Bristol-Myers Squibb Company offers a range of cancer treatments, including immunotherapies, competing in the oncology market.
Moderna
MRNA
Mkt Cap88.52B
Moderna, Inc. is known for mRNA vaccines but is expanding into cancer vaccines, potentially competing with NWBO's technology.
Pfizer
PFE
Mkt Cap173.95B
Pfizer Inc. has a broad oncology portfolio, including investments in immunotherapies, competing in the cancer treatment market.
Astrazeneca
AZN
Mkt Cap289.48B
AstraZeneca PLC has a diverse oncology portfolio, including immunotherapies, competing across various cancer treatment areas.

About

Northwest Biotherapeutics, Inc. (NWBO) is a biotechnology firm that creates personalized immune-based treatments for various cancers, operating both within the United States and internationally. Their product pipeline relies on DCVax, a proprietary technology platform. This platform harnesses a patient's own activated dendritic cells to stimulate their immune system to combat cancerous cells. The company's leading therapeutic candidate, DCVax-L, has successfully completed Phase III clinical trials targeting Glioblastoma multiforme, an aggressive form of brain cancer. Additionally, Northwest Biotherapeutics is progressing DCVax-Direct through Phase I/II clinical studies, focusing on the treatment of inoperable solid tumors. Founded in 1996, the company's headquarters are situated in Bethesda, Maryland.
Show More
CEO
Linda F. Powers
Employees
105
Country
United States
ISIN
US66737P6007

Listings

STU
DE
NBYB.STU
LSE
GB
0K95.LSE
OTC Link
US
NWBO

0 Comments

Share your thoughts

FAQs

What is Northwest Biotherapeutics stock price today?▼
The current price of NBYB.STU is €0.16 EUR — it has increased by +23.08% in the past 24 hours. Watch Northwest Biotherapeutics stock price performance more closely on the chart.
What is Northwest Biotherapeutics stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on Boerse Stuttgart exchange Northwest Biotherapeutics stocks are traded under the ticker NBYB.STU.
Is Northwest Biotherapeutics stock price growing?▼
NBYB.STU stock has risen by +6.67% compared to the previous week, the month change is a +18.52% rise, over the last year Northwest Biotherapeutics has showed a -32.77% decrease.
What is Northwest Biotherapeutics market cap?▼
Today Northwest Biotherapeutics has the market capitalization of 267.09M
What is Northwest Biotherapeutics revenue for the last year?▼
Northwest Biotherapeutics revenue for the last year amounts to 1.2M EUR.
What is Northwest Biotherapeutics net income for the last year?▼
NBYB.STU net income for the last year is -53.74M EUR.
How many employees does Northwest Biotherapeutics have?▼
As of November 2, 2026, the company has 105 employees.
In which sector is Northwest Biotherapeutics located?▼
Northwest Biotherapeutics operates in the Health & Wellness sector.
When did Northwest Biotherapeutics complete a stock split?▼
The last stock split for Northwest Biotherapeutics was on September 26, 2012 with a ratio of 1:16.
Where is Northwest Biotherapeutics headquartered?▼
Northwest Biotherapeutics is headquartered in Bethesda, United States.